HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
NATCO Pharma investing $14 million in eGenesis
Aug-25-2026

NATCO Pharma is investing $14 million in eGenesis, Inc. through its wholly owned subsidiaries, NATCO Pharma (Canada) Inc. for an amount of $9.5 million and NATCO Pharma South Africa Proprietary for an amount of $4.5 million, though convertible promissory notes. Previously in 2024, NATCO Pharma had invested $8 million in eGenesis, Inc. through preferred stock. The total investment made by NATCO Pharma in eGenesis, Inc. now stands at $22 million.

eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure.

NATCO Pharma develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US.

  RELATED NEWS >>